ReviewThe Lancet. Respiratory medicine2025
Post-tuberculosis lung disease: towards prevention, diagnosis, and care.
Review in The Lancet. Respiratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pulmonary rehabilitation in post-tuberculosis lung disease: a systematic review.Frontiers in medicine · 2026Pooled it
- Prevalence and impacts of breathlessness in South Africa: an exploratory, cross-sectional population study.Journal of global health · 2026Article
- Bronchoscopic Closure of Bronchopleural Fistula Using Silver Nitrate in a Child with Post-Tubercular Lung Sequelae and Necrotizing Pneumonia.Indian pediatrics · 2026Article
- Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.MedComm · 2026Review
- Treatment outcomes and post-treatment mortality among people with multidrug/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study.The Lancet regional health. Africa · 2026Article
- Asthma Incidence and Risk Factors in Tuberculosis Survivors: A Longitudinal Analysis of National Health Data.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Posttuberculosis Consequences on Tuberculosis Prevention Effectiveness and Cost-effectiveness among New Immigrants, Canada.Emerging infectious diseases · 2026Article
- Successful Treatment of Mycobacterium caprae Infection in Two UK Cats.Veterinary medicine and science · 2026Article
- Beyond Cure: A Scoping Review of Post-Tuberculosis Long-Term Health Outcomes.Tropical medicine and infectious disease · 2026Review
- Delays in Tuberculosis Treatment Among People With Pulmonary Tuberculosis in East Africa: Findings From a Prospective Cohort Study.Open forum infectious diseases · 2026Article
- Tuberculosis and Post-Tuberculosis Lung Changes Are Associated with Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease: A Population-Based Retrospective Cohort Study.Journal of personalized medicine · 2026Article
- Artificial Intelligence-Assisted Quantification of Longitudinal HRCT Changes During Treatment of Pulmonary Tuberculosis: An Exploratory Proof-of-Concept Study.Diagnostics (Basel, Switzerland) · 2026Article
- Severe Post-Tuberculosis Bronchiectasis With Bullous Lung Disease Complicated by Acute Infective Exacerbation: A Case Report From Uganda.Clinical case reports · 2026Article
- Clinical and transcriptomic risk factors for post-tuberculosis lung disease in a cohort of Kenyan adults.American journal of respiratory and critical care medicine · 2026Observational
- High prevalence of persistent tuberculosis-related symptoms 6 months after treatment in pulmonary tuberculosis.BMJ open respiratory research · 2026Observational
- Epidemic trends and characteristics of notifiable infectious diseases in mainland China during the COVID-19: a nationwide surveillance study, 2020-2024.Journal of global health · 2026Article
- Post-tuberculosis Health: A Holistic Perspective on Multisystem Sequelae and Long-Term Wellbeing.Tuberculosis and respiratory diseases · 2026Article
- Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in patients with tuberculosis-associated chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.Journal of thoracic disease · 2026Article
- Personal PM2.5 exposure and lung function among adults with and without HIV who have recovered from pneumonia in Kampala, Uganda.Annals of the American Thoracic Society · 2026Article
- Tuberculosis: So much accomplished and so much more to be done.The Indian journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
There is a growing body of data describing the high burden of respiratory sequelae seen among tuberculosis survivors, including children, adolescents, and adults. This group of sequelae are known as post-tuberculosis lung disease and include parenchymal damage, airway disease, and pulmonary vascular disease. It is thought that approximately half of pulmonary tuberculosis survivors have ongoing structural pathology, lung function impairment, or respiratory symptoms after the resolution of active disease. Post-tuberculosis lung disease has been associated with adverse patient outcomes, including persistent symptoms and functional impairment, ongoing health seeking, and impacts on income and employment. There is still much to understand about the epidemiology and nature of post-tuberculosis lung disease, but in this Review we focus on strategies for prevention, diagnosis, and care to inform the ongoing work of tuberculosis-affected communities, health-care providers, researchers, and policy makers. We summarise recent data, highlight evidence gaps, and suggest key research priorities for those working in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.